President & CEO Message


   At Luminor Medical, we are dedicated to introducing and commercializing new and innovative diagnostic and risk  assessment technologies to aid healthcare providers in the earlier diagnosis of disease. We also continue to explore new  partnerships, acquisition, growth and development.  Our goal is to make individuals and institutions aware of their  potential risk and to encourage them to seek out/provide appropriate medical care and guidance, in order to effectively  manage their disease. We strive to improve the quality of patients’ lives, save lives, and reduce healthcare costs  associated with chronic care management.We are currently focused on our our lead technology – the Scout DS® Diabetes  Screen. This technology is non-invasive and user-friendly, without requiring needles, blood draw, fasting, or waiting.  These are all the critical characteristics and qualities necessary to encourage people as never before to get screened for risk of pre-diabetes and type 2 diabetes – the fastest growing disease in history.  By taking just a few minutes, individuals can receive important information about their health that is affordable and actionable in real time.

According to the World Health Organization (WHO), an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. The global prevalence (age-standardized) of diabetes has nearly doubled since 1980.  It is estimated that more than 40% of these are undiagnosed. In addition, 1.1 billion people are estimated to be pre-diabetic, with approximately 90% of these being completely unaware of their condition.  Diabetes caused 1.5 million deaths in 2012. High blood glucose  (pre-diabetes) caused an additional 2.2 million deaths, by increasing the risks of cardiovascular and other diseases. Forty-three percent of these 3.7 million deaths occur before the age of 70 years.

Luminor is a publicly traded biotechnology company specializing in the manufacture of medical testing and screening devices for people with diabetes, high blood glucose and cardio-vascular risks. We continue to be funded by our many stakeholders around the world and are grateful for their continued support and shared vision. I invite you to review our web sites to learn more about the company, our current activities and operations, and our plans for the future.

Christian Sauvageau
President and Chief Executive Officer